Executive Summary

Achieving safe and effective liver-directed gene therapy requires a vector construct that balances hepatocyte transduction efficiency, payload expression, and immunological stealth. The selection of the AAV serotype and the design of the expression cassette are foundational decisions that directly influence a program’s trajectory. Early, data-driven consultation on vector architecture is a primary de-risking activity, setting the stage for a more predictable path toward IND submission.

Optimizing Vector Constructs for Hepatocyte Targeting

The liver remains a primary target for in vivo gene therapy due to its accessibility and central role in metabolic function. Successful therapeutic outcomes depend on designing an AAV vector that can efficiently transduce hepatocytes while limiting expression elsewhere. This begins with capsid selection. Serotypes such as AAV8 have demonstrated robust liver tropism, yet the challenge of pre-existing immunity requires a sophisticated approach. Data show that chimeric capsids, such as AAV2/8, can achieve sustained correction even in the context of prior exposure to a parental serotype, underscoring the value of strategic capsid engineering to overcome specific immunological hurdles (PMID: 15637142).

Beyond the capsid, the architecture of the expression cassette is a key determinant of the safety and efficacy profile. The choice of promoter dictates the specificity of transgene expression. A poorly chosen promoter may lead to sufficient expression in non-target tissues to cause unwanted biological activity. Utilizing well-characterized, liver-specific promoters is a fundamental design principle for containing expression within the target organ.

Learn more about capsid engineering and other factors for AAV programs in the full-length webinar: Vector Ready: Where AAV projects begin and how they succeed.

A Data-Driven Approach to Vector Design

A robust vector design is validated by a comprehensive analytical strategy. Our approach integrates vectorology expertise with deep analytical capabilities to ensure every construct is well-characterized. As one of our partners noted, our team provides “Wonderful services. Excellent team to work with. Vast knowledge in all aspects of vector production and analytics.” This continuity of expertise, originating from the UPenn Vector Core and now driving Franklin Biolabs, provides sponsors with a clear development roadmap.

Our teams, operating within a >100,000 sq ft facility, provide Strategic Design Guidance Accelerating Development Lifecycles. We align vector design with manufacturing and analytical considerations from day one, helping our partners navigate the complexities of AAV biology to build a robust data package for a targeted 18-24 month IND timeline.